The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Nanoveu (NVU) has signed a memorandum of understanding (MOU) with Cupron for a supply of copper iodide metal powder
  • The twelve-month, non-exclusive MOU covers the supply of the “Cupron Enhanced Product” (CEP) for use in Nanoveu’s antiviral technology products sold in the U.S.
  • Under the MOU, Nanoveu will be offered a fixed price for CEP material, with Cupron receiving a sales royalty on U.S.-based Nanoshield sales
  • Nanoveu shares are up 9.84 per cent, trading at 6.7 cents

Nanoveu (NVU) has signed a memorandum of understanding (MOU) with Cupron for a supply of copper iodide metal powder for use in its antiviral and antimicrobial products.

Cupron is a copper-based antimicrobial technology company based in Delaware, U.S., which harnesses the unique properties of copper for healthcare, consumer, industrial and military applications.

The MOU is for a twelve-month, non-exclusive supply of the “Cupron Enhanced Product” (CEP) for use in Nanoveu’s products sold in the U.S.

Under the MOU, Nanoveu will be offered a fixed price for CEP material, with Cupron receiving a royalty on U.S.-based Nanoshield sales. Cupron will receive 8 per cent royalties for the first U.S.$1 million sales (roughly A$1.29 million), 6 per cent for up to U.S.$10 million (around A$12.9 million) in sales, and 4 per cent of all sales thereafter.

“This is a particularly important MOU which will see Nanoveu increase its avenues to generate sales in the massive market of the USA,” said Nanoveu Executive Chairman and CEO Alfred Chong.

CEP material is registered under the United States Environmental Protection Agency (EPA). The new agreement will also see Nanoveu sell its Nanoshield product using CEP under Cupron’s EPA registration.

The Nanoshield product, a protective film using a transparent resin with activated copper, is capable of using CEP without affecting its efficacy or production profile.

Cupron’s EPA approval allows products using CEP to make a number of claims, including the provision of antimicrobial protection, prevention of bacteria, mould, fungi, and mildew growth, plus the ability to keep surfaces cleaner for longer periods.

Cupron will also aim to receive approval from the EPA for a new public health claim relating to antiviral properties, based on its existing registration.

“The use of Cupron’s material will allow us much greater flexibility in the way the product is applied and marketed. It also opens up a host of new areas that is only possible with regulatory approval,” said Alfred Chong.   

Nanoveu’s antiviral technology has been independently demonstrated to be a highly effective agent for the eradication of viruses, eliminating 99.9 per cent of a viral strain affecting humans that is also a surrogate for COVID-19, within 30 minutes.

Nanoveu shares are up 9.84 per cent, trading at 6.7 cents at 12:05 pm AEST.

NVU by the numbers
More From The Market Online

Iress (ASX: IRE) strikes deal with Bain Capital for UK Mortgage Business Sale

Iress (ASX:IRE) has entered into a binding agreement to sell its UK Mortgage business to Bain…

Dotz Nano advances climate solutions with ‘Dotz Earth’

Dotz Nano is a leading developer of innovative climate and industrial technologies – and it's got…
The Market Online Video

Orcoda welcomes Maree Adshead as Non-Executive Director

Orcoda (ASX:ODA) has welcomed Maree Adshead as an independent Non-Executive Director.